New pill targets multiple advanced cancers in early trial
NCT ID NCT06926075
Summary
This early-stage trial is testing a new oral drug called KESONOTIDE in people with advanced solid tumors that have spread. The main goal is to find a safe dose and see how well the body handles the medicine. About 80 adults with cancers like prostate, breast, lung, ovarian, and others will take the pill every three weeks until their cancer worsens or side effects become too strong.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
South Western Sydney Local Health District
RECRUITINGLiverpool, New South Wales, 2170, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Southside Cancer Centre
RECRUITINGMiranda, New South Wales, 2228, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
St George Private Hospital
RECRUITINGKogarah, New South Wales, 2217, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.